Innovotech Inc.

Innovotech Inc.

September 09, 2005 14:32 ET

Innovotech Inc.: MBEC BioProducts Inc. Files Provisional Patent for Diagnostic Susceptibility Test

EDMONTON, ALBERTA--(CCNMatthews - Sept. 9, 2005) - Innovotech Inc. (TSX VENTURE:IOT) is pleased to announce that its wholly owned subsidiary, MBEC BioProducts Inc., has recently filed a provisional patent to expand the use of its core patented technology to assist physicians in the selection of antibiotics for biofilm diseases including cystic fibrosis lung infections, artificial hip and knee infections, and vascular catheter infections.

MBEC is capitalizing on the opportunity that no currently available laboratory diagnostic test can determine which antibiotics to select for a biofilm infection. The standard MIC (Minimum Inhibitory Concentration) test, for example a throat swab, is appropriate only for free-floating bacteria not biofilm bacteria. Yet it is widely known that biofilms can be up to 1,000 times less susceptible to antibiotics than the very same organism in a free-floating state and that over 60% of all human infections are caused by organisms in a biofilm state (Center for Disease Control and Prevention, 2000). Worldwide, approximately 35 million MIC tests are conducted annually. The MBEC test will provide physicians with a patient specific test to assist in antibiotic selection.

Innovotech Inc. is a public company focused on acquiring novel technologies, or promising technology based companies with an existing or imminent revenue stream. In addition to financial investment in these technologies, Innovotech provides management and technology commercialization expertise.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contact Information

  • Innovotech Inc.
    Dr Gerard Tertzakian
    (780) 448-0585
    (780) 424-0941 (FAX)
    MBEC BioProducts
    Ken Boutilier
    (780) 452-8687
    (780) 452-8807 (FAX)